OCUGEN, INC. Noncash Merger Related Costs
OCUGEN, INC. (OCGN) reported Noncash Merger Related Costs of $0 for the 12-month period ending 2021-12-31, per its 10-K filed 2022-02-28.
Discontinued › Cash Flow › Operating Activities
us-gaap:NoncashMergerRelatedCosts · last filed 2022-02-28
- OCUGEN, INC. noncash merger related costs for fiscal 2021 was $0.00.
- OCUGEN, INC. noncash merger related costs for fiscal 2020 was $0.00, a 100.00% decline from fiscal 2019.
- OCUGEN, INC. noncash merger related costs for fiscal 2019 was $2.25M.
| Period end | Noncash Merger Related Costs 12 month |
|---|---|
| 2021-12-31 | $0.00 10-K · filed 2022-02-28 |
| 2020-12-31 | $0.00 10-K · filed 2022-02-28 |
| 2019-12-31 | $2.25M 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |